Trials / Completed
CompletedNCT02736240
Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)
Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Developed Cooperatively by YunNan Walvax Biotechnology Co., Lt and Yuxi Walvax Biotechnology Co., Lt Among 2-71 Months (the Youngest Could be 6 Weeks) Healthy Infants and Toddlers by Randomized Blind Method With Similar Control in Multi-centers.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,760 (actual)
- Sponsor
- Walvax Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Months – 71 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate and valuate the immunogenicity and safety of the 13-valent pneumococcal polysaccharide conjugate vaccine in 2-71 months old healthy infants and toddlers (the youngest could be 6 weeks old)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 7-valent pneumococcal conjugate vaccine | |
| BIOLOGICAL | 13-valent pneumococcal polysaccharide conjugate vaccine |
Timeline
- Start date
- 2016-04-08
- Primary completion
- 2017-12-03
- Completion
- 2017-12-03
- First posted
- 2016-04-13
- Last updated
- 2020-10-14
Source: ClinicalTrials.gov record NCT02736240. Inclusion in this directory is not an endorsement.